Genetic Engineers apply precise techniques to modify the DNA of organisms, enabling advancements that impact medicine, agriculture, and environmental science. Through tools like CRISPR-Cas9, gene cloning, and recombinant DNA technology, they alter genetic material to enhance traits, correct mutations, or develop entirely new capabilities within cells. In healthcare, genetic engineers are at the forefront of developing gene therapies for inherited disorders, engineering immune cells to fight cancer, and advancing treatments for rare diseases. Their work also plays a critical role in the development of genetically modified organisms (GMOs), which can improve crop yield, resistance to pests, and tolerance to climate stress.
In industrial and research settings, genetic engineers collaborate with molecular biologists, biotechnologists, and data scientists to translate complex genetic insights into practical applications. Their innovations extend to synthetic biology, where they design new biological systems with potential in pharmaceuticals, biofuels, and biodegradable materials. Ethical and safety considerations are an integral part of their work, as they navigate the challenges of genome editing with responsibility and precision. By unlocking the ability to engineer life at the genetic level, they contribute to breakthroughs that have the potential to transform entire industries. Their expertise is reshaping our understanding of biology and redefining what is possible in science and technology. As the boundaries of genetic science expand, genetic engineers remain central to innovation that benefits both humanity and the planet.
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Approaches towards developing and establishing a biomanufacturing research & development, and manufacturing industry in Zimbabwe: A review of the need, potential funding sources, policy development and implementation
Elliot Nyagumbo, Midlands State University, Zimbabwe
Title : Evaluating the immunogenic impact of process impurities in mRNA vaccine production: Establishing integrated control strategies and specifications
Jesse Kuiper, Merck Research Laboratories, United States
Title : Capillary electrophoresis for adjuvanted multivalent recombinant vaccine purity determination
Ashley Prout, Merck, United States
Title : Hypersensitivity and anti-SARS-COV-2 vaccination: A retrospective study of the year 2021 at the University Hospital Center of Tours (France)
Faure Quentin, The Savoie Metropolitan Hospital Center, France
Title : THE HPV vaccination program in Colombia. From a beautiful dream to a nightmare, but hopefully with a bright dawn.
Carlos Castro, Colombian League against cancer, Colombia